Real-World Analysis of the Enfortumab Vedotin-Ineligible criTeriA Assessment in Treatment-Naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

被引：0

作者：

Miyake, Makito ^{[1
]}

Nishimura, Nobutaka ^{[1
]}

Oda, Yuki ^{[1
]}

Shimizu, Takuto ^{[1
]}

Iida, Kota ^{[1
]}

Fujimoto, Kiyohide ^{[1
]}

机构：

[1] Nara Med Univ, Dept Urol, Nara, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2025年

关键词：

chemotherapy; enfortumab vedotin; EVITA; mortality; pembrolizumab; survival; urinary bladder neoplasms;

D O I：

10.1111/iju.70040

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：3

共 50 条

[31] Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-na⟨ve Patients: a Systematic Review and Network Meta-Analysis
Schmidt, Elvira
Lister, Johanna
Neumann, Monika
Wiecek, Witold
Fu, Shuai
Vataire, Anne-Lise
Sostar, Jelena
Huang, Shengnan
Marteau, Florence
TARGETED ONCOLOGY, 2018, 13 (02) : 205 - 216
[32] Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy
Hepp, Zsolt
Shah, Sonali N.
Liang, Shang-Ying
Tan, Katherine
Balakrishna, Shreya
FUTURE ONCOLOGY, 2021, 17 (32) : 4343 - 4353
[33] The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis
Huang, Shih-Yu
Su, Po-Jung
Lin, Chang-Ting
Kuo, Ming-Chun
Chen, Yi-Hua
Wu, Chia-Che
Luo, Hao-Lun
Chen, Chien-Hsu
Chou, Chih-Chi
Huang, Chun-Chieh
Kuo, Chung-Wen
Su, Yu-Li
CANCER MEDICINE, 2024, 13 (02):
[34] Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program
Monteiro, Fernando Sabino M.
e Silva, Adriano Goncalves
Gomes, Andrea Juliana P. de S.
Dutra, Carolina
Ferreira, Naira Oliveira
Mariano, Rodrigo Coutinho
Schutz, Fabio A.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[35] Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Santoni, Matteo
Myint, Zin W.
Buettner, Thomas
Takeshita, Hideki
Okada, Yohei
Lam, Elaine T.
Gilbert, Danielle
Kueronya, Zsofia
Tural, Deniz
Pichler, Renate
Grande, Enrique
Crabb, Simon J.
Kemp, Robert
Massari, Francesco
Scagliarini, Sarah
Iacovelli, Roberto
Vau, Nuno
Basso, Umberto
Maruzzo, Marco
Molina-Cerrillo, Javier
Galli, Luca
Bamias, Aristotelis
De Giorgi, Ugo
Zucali, Paolo Andrea
Rizzo, Mimma
Seront, Emmanuel
Popovic, Lazar
Caffo, Orazio
Buti, Sebastiano
Kanesvaran, Ravindran
Kopecky, Jindrich
Kucharz, Jakub
Zeppellini, Annalisa
Fiala, Ondrej
Landmesser, Johannes
Ansari, Jawaher
Giannatempo, Patrizia
Rizzo, Alessandro
Zabalza, Ignacio Ortego
Monteiro, Fernando Sabino M.
Battelli, Nicola
Calabro, Fabio
Porta, Camillo
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2961 - 2970
[36] Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni
Zin W. Myint
Thomas Büttner
Hideki Takeshita
Yohei Okada
Elaine T. Lam
Danielle Gilbert
Zsófia Küronya
Deniz Tural
Renate Pichler
Enrique Grande
Simon J. Crabb
Robert Kemp
Francesco Massari
Sarah Scagliarini
Roberto Iacovelli
Nuno Vau
Umberto Basso
Marco Maruzzo
Javier Molina-Cerrillo
Luca Galli
Aristotelis Bamias
Ugo De Giorgi
Paolo Andrea Zucali
Mimma Rizzo
Emmanuel Seront
Lazar Popovic
Orazio Caffo
Sebastiano Buti
Ravindran Kanesvaran
Jindrich Kopecky
Jakub Kucharz
Annalisa Zeppellini
Ondřej Fiala
Johannes Landmesser
Jawaher Ansari
Patrizia Giannatempo
Alessandro Rizzo
Ignacio Ortego Zabalza
Fernando Sabino M. Monteiro
Nicola Battelli
Fabio Calabrò
Camillo Porta
Cancer Immunology, Immunotherapy, 2023, 72 : 2961 - 2970
[37] Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany
Kramb, Felix
Doerfer, Christoph
Meiwes, Andreas
Ramakrishnan, Karthik
Eigentler, Thomas
Garbe, Claus
Keim, Ulrike
Leiter, Ulrike
ACTA DERMATO-VENEREOLOGICA, 2022, 102
[38] Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
Zhou, Fei
Guo, Haoyue
Zhou, Xiaolong
Xie, Huikang
Tian, Tian
Zhao, Wencheng
Gao, Guanghui
Xiong, Anwen
Wang, Lei
Li, Wei
Chen, Xiaoxia
Zhang, Yan
Fan, Jue
Wu, Fengying
Zhang, Yongchang
Zhou, Caicun
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[39] Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
Matsubara, Nobuaki
Yonese, Junji
Kojima, Takahiro
Azuma, Haruhito
Matsumoto, Hiroaki
Powles, Thomas
Rosenberg, Jonathan E.
Petrylak, Daniel P.
Matsangou, Maria
Wu, Chunzhang
Campbell, Mary
Yamashiro, Mayumi
CANCER MEDICINE, 2023, 12 (03): : 2761 - 2771
[40] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, Arjun V.
Galsky, Matthew D.
Rosenberg, Jonathan E.
Powles, Thomas
Petrylak, Daniel P.
Bellmunt, Joaquim
Loriot, Yohann
Necchi, Andrea
Hoffman-Censits, Jean
Perez-Gracia, Jose Luis
Dawson, Nancy A.
van der Heijden, Michiel S.
Dreicer, Robert
Srinivas, Sandy
Retz, Margitta M.
Joseph, Richard W.
Drakaki, Alexandra
Vaishampayan, Ulka N.
Sridhar, Srikala S.
Quinn, David I.
Duran, Ignacio
Shaffer, David R.
Eigl, Bernhard J.
Grivas, Petros D.
Yu, Evan Y.
Li, Shi
Kadel, Edward E., III
Boyd, Zachary
Bourgon, Richard
Hegde, Priti S.
Mariathasan, Sanjeev
Thastrom, AnnChristine
Abidoye, Oyewale O.
Fine, Gregg D.
Bajorin, Dean F.
LANCET, 2017, 389 (10064) : 67 - 76

← 1 2 3 4 5 →